CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07299838
NCT07299838N/ACompleted

Real-World Data for Effectiveness and Safety of Palopegteriparatide in Patients With Chronic Hypoparathyroidism in Greece

National and Kapodistrian University of Athens·observational·Posted Dec 23, 2025·Updated Jan 26, 2026

In Brief

An observational study for Hypoparathyroidism. Completed, enrolled 90 participants across 1 site.

Detailed Summary

This is a multicenter, prospective cohort study conducted across 9 tertiary and university hospitals in the rural area of Athens, which investigates the clinical and biochemical effects of palopegteriparatide (TransCon PTH) in adult patients with chronic hypoparathyroidism (≥12 months). Eligible participants included those transitioning from conventional therapy (activated vitamin D analogs and oral calcium) and those previously treated with rhPTH(1-84). The primary objective was to assess the time to independence from activated vitamin D and calcium supplementation. Secondary objectives included changes in biochemical parameters, incidence of clinically significant hypo- and hypercalcemia during the titration period , and reduction in daily pill burden. Patients received individualized doses of palopegteriparatide with follow-up visits at regular intervals, and safety was monitored throughout the study according to standard clinical practice.

Study Details

Timeline

N/ACompletedFinished
20252026
First PostedDec 23, 2025
Enrollment StartJun 1, 2024
Primary CompletionSep 30, 2025
Study CompletionOct 23, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6 months ago